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The human gut is populated by a microbiota composed of tens of trillions of organisms and millions of genes
that together form a metabolic ‘‘organ.’’ Intra- and interpersonal differences in the structure and functions of
this organ suggest that it could contribute to our normal metabolic variations and also tometabolic disorders.
This Commentary discusses experimental approaches for connecting microbial and host metabolism in the
context of health and disease.Introduction
Here is a striking and perhaps humbling
perspective about ourselves: Approxi-
mately 10 percent of our cells and <1
percent of our genes are human; the
remainder are microbial (Savage, 1977).
The vast majority of these microbes (tens
of trillions), representing all three domains
of life, live in our gastrointestinal tracts.
The enormous genetic repository (micro-
biome) encoded in our gut microbial
community (microbiota) differs from our
human genome in terms of its origin (we
are born in a pristine, essentially germ-
free state), composition, plasticity, and
extent of interpersonal diversity (Costello
et al., 2009; Qin et al., 2010; Turnbaugh
et al., 2010). Even essentially genetically
identical adult monozygotic cotwins
harbor distinct collections of microbial
species and genes in their guts (Turn-
baugh et al., 2009a, 2010). This leads to
the thought that we each house personal
metabolic organs within our gastrointes-
tinal tracts, composed of microbial cell
lineages bound together in an elaborate
coevolved web of interspecies and inter-
kingdom metabolic commerce that could
have a profound impact on our metabolic
phenotypes (metabotypes).
The potential to develop new microbial
diagnostic biomarkers of our metabolic
status, and new therapeutic strategies to
maximize the contribution of our micro-
biota to our health, has spawned many
human microbiome projects (HMPs)
worldwide. These HMPs reflect the rapid
coevolution of new experimental and
computational tools that together form
a field known as ‘‘metagenomics,’’ which
uses culture-independent, sequencing-based methods to characterize the
composition and dynamic operations of
microbial communities.
Much of what we consume, both bene-
ficial and noxious, is first encountered
and processed by our gut microbes. Our
current understanding of the connections
between metabolism, diet, and the micro-
biota has been the subject of several
recent reviews (e.g., Ba¨ckhed and Craw-
ford [2010] and Musso et al. [2010]). The
goals of this Commentary are to (1) high-
light experimental approaches that are
likely to play important roles in forging
connections between the microbiota and
host metabolism, (2) discuss some of the
challenges facing the field and how they
might be addressed, and (3) envision ther-




The proportion and phylogenetic distribu-
tion of human gut microbial species that
are recalcitrant to culture in vitro has not
been clearly established. Nonetheless,
culture-independent techniques have
made important contributions to our cur-
rent understanding of these microbial
populations and how they may both
induce and respond tometabolic changes
in their hosts. Many of these culture-inde-
pendent techniques are closely linked
to advances in DNA-sequencing tech-
nology: e.g., microbial community com-
position profiling via targeted sequencing
of small subunit (SSU) ribosomal RNA
genes; shotgun sequencing to predict
encoded functions; and defining which
functions are expressed by profilingCell Metabolism 1mRNAs emanating from the microbiome.
We can safely predict that the breadth
and depth of microbial community sam-
pling will change significantly as the
throughput of highly parallel sequencing
instruments continues to increase rapidly
(Caporaso et al., 2010). For example,
descriptions of human gut microbial
communities that assimilate the results
of detailed time-course studies of ever
larger numbers of individuals living in
distinct cultural contexts will be critical
for determining how lifestyle (diet and
other environmental exposures) impacts
community structure and functions, and
for defining healthy versus disease-rele-
vant community configurations.
In addition to these sequencing-based
approaches, culture-independent identifi-
cation and quantification of proteins and
metabolites by MS or NMR will be critical
to connect the gut microbiota to metabo-
lism of exogenously as well as endoge-
nously derived molecules. Comparisons
of blood metabolites in germ-free and
conventionally raised mice using nontar-
geted MS have revealed hundreds of
compounds that are detectable in one
but not the other type of animal, and
even more whose concentrations are
affected by the microbiota (Wikoff et al.,
2009). For example, many compounds
are conjugated to charged moieties such
as sulfate, glycine, and glucoronide only
in the presence of a microbiota: as these
adducts are involved in the processing
of xenobiotics, this finding suggests
that the microbiota could determine indi-
vidual responses to many drugs that are
metabolized either inside or outside of
the intestine. These results translate to2, August 4, 2010 ª2010 Elsevier Inc. 111
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acetaminophen to either sulfonated or
glucoronidated forms has been associ-
ated with predose levels of p-cresol,
a microbial tyrosine metabolite that com-
petes with acetaminophen for its sulfo-
nate donor and the relevant sulfotransfer-
ase enzyme. Higher levels of p-cresol
correlate with decreased sulfonation and
increased glucoronidation of acetamino-
phen (Clayton et al., 2009).
Siuzdak and colleagues have used
nontargeted MS to identify a metabolite,
indole-3-propionic acid (IPA), in the serum
of conventionally raised but not germ-free
mice. This compound is an antioxidant
and a potential therapeutic agent for
Alzheimer’s disease. They subsequently
screened cultured human gut symbionts
and found a species, Clostridium sporo-
genes, capable of producing IPA in vitro.
When introduced into the guts of germ-
free mice, C. sporogenes is capable of
restoring serum IPA to levels encountered
in their conventionally raised counterparts
(Wikoff et al., 2009). In another example,
nontargeted MS-based analyses of age-
matched and genetically identical germ-
free versus conventionally raised mice
(Velagapudi et al., 2010) have indicated
that there is increased trafficking of
triglycerides between the circulation and
adipose storage depots in animals with
a microbiota. Concurrent increases in
serum and liver levels of phosphatidyl-
choline (16:0/18:1), an agonist of the
lipoprotein lipase (LPL) transcriptional
activator PPAR-a, are consistent with
other observations that PPAR-a gene
expression can be activated by the gut
microbiota (Crawford et al., 2009). Micro-
biota-dependent suppression of intestinal
epithelial expression of Fiaf (Angptl4),
a circulating LPL inhibitor, also contrib-
utes to increased triglyceride storage in
adipocytes (Velagapudi et al., 2010).
Engraftment of Complete
Microbiotas into Germ-Free Mice
Several difficult-to-control variables com-
plicate studies of themetabolic properties
of the gut microbiota in humans, including
differences in host genotypes, incomplete
histories of food consumption and prior
environmental exposures, the absence
of replicate individuals with identical gut
microbial communities, and limitations
in sampling more remote regions of
the gastrointestinal tract. Gnotobiotic
(‘‘known life’’) animals, in which microbes112 Cell Metabolism 12, August 4, 2010 ª201are either entirely absent (germ-free) or
intentionally introduced at selected times,
provide an approach for connecting
microbial communities and their genes
to host metabolism (Figure 1A). Encour-
agingly, culture-independent SSU (16S)
rRNA-based community composition
analysis suggests that the great majority
of the bacterial diversity present in
a human fecal microbiota (even samples
archived at 80C for more than a year)
can be stably engrafted into germ-free
mice (Turnbaugh et al., 2009b). Intergen-
erational transfer of the human gut micro-
biota from these humanized mice to their
offspring produces animals that inherit
a foreign microbiota ‘‘naturally,’’ and
thus allows experiments to be performed
and hypotheses to be generated about
how human gut microbial community
assembly may shape and even imprint
a host metabotype in animals where the
innate and adaptive arms of the immune
system coevolve with the microbiota
from birth. Transplantation of gut commu-
nities from human donors with different
metabotypes to germ-free animals with
or without (host) genetic mutations postu-
lated to contribute to donor phenotypes,
and who do or do not consume diets
analogous to those of the donors, allows
proof-of-principle, proof-of-mechanism
studies to be performed. These studies
could directly address the question of
how much of a host’s physiologic charac-
teristics are a reflection of traits encoded
in their microbiome versus their human
genome, and how environmental factors,
such as diet, contribute to eliciting a me-
tabotype.
Other examples have also highlighted
the utility of transplanting foreign
microbiotas into germ-free mice. In a
recent study, mice lacking toll-like
receptor 5 (TLR5) exhibited several fea-
tures of metabolic syndrome: increases
in adiposity, serum triglycerides and
cholesterol, hyperinsulinemia, as well as
reduced response to insulin challenge
(Vijay-Kumar et al., 2010). TLR5, which
recognizes bacterial flagellin, is highly
expressed in the intestine. Antibiotic
treatment, coupled with 16S rRNA pyro-
sequencing, suggested that changes in
distal gut microbiota community compo-
sition correlate with these metabolic
features. Importantly, transplantation of
the distal gut microbiota from TLR5
knockout animals to wild-type germ-0 Elsevier Inc.free recipients transmitted many of
these phenotypic characteristics to the
recipients.
Synthetic Human Gut Communities
Transplantation of a complete microbiota
into germ-free mice allows host and
environmental factors to be controlled,
but the microbial component of these
experiments remains difficult to com-
pletely describe or manipulate. Gnotobi-
otic mice provide an opportunity for
defining the metabolic properties of
synthetic human gut microbial communi-
ties composed of selected sets of cul-
tured representatives of a human (gut)
microbiota; these representatives can be
chosen from private or public culture
collections based on a number of criteria
including their consistent association
with specific human metabolic states
and their representation in a fecal micro-
biota that when transferred en masse
confers a metabotype to recipient germ-
free mice. They can also be selected
based on their phylogenetic features as
defined by SSU rRNA gene sequencing,
and/or by the results of in silico predic-
tions of their metabolic potential based
on their genome sequences (Martin
et al., 2007).
Members of these assembled model
human microbial communities can be
systematically removed or replaced prior
to colonization of germ-free recipient
mice to test the connections between
microbiota composition and the meta-
bolic consequences for a host. These
synthetic microbial communities also pro-
vide an opportunity to directly identify
genes that human gut symbionts require
in specific in vivo contexts. Such genes
can (1) highlight microbial metabolic path-
ways that are critical to competitive
fitness in certain host or microbial con-
texts, (2) provide a mechanistic basis for
observed changes in microbial commu-
nity structure in response to various
perturbations, and (3) include potential
targets for therapeutic manipulation of
the gut microbiota by small-molecule
or other approaches. Insertion sequenc-
ing (INSeq), a method that combines
genome-wide transposon mutagenesis
withmassively parallel sequencing, repre-
sents one approach for identifying such
genes (Goodman et al., 2009). In this
approach, complex populations of tens
of thousands of transposon mutants are
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Figure 1. Connecting Microbiota and Metabolism through Gnotobiotics
(A) A complete human gut (fecal) microbiota, obtained from individuals varying in their diet or physiology, can be surveyed by highly parallel DNA-, RNA-, protein-,
and metabolite-directed methods. These microbial communities also serve as source material for transplantation into germ-free mice. They can also be fraction-
ated into component species and assembled into ‘‘synthetic communities’’ of defined composition in order to directly test the roles of specific phylotypes in
shaping host physiology: these phylotypes can be intentionally added, removed, or substituted with mutagenized populations prior to colonization of germ-
free animals to identify genes required for fitness in specific host/dietary contexts using a method known as insertion sequencing (INSeq).
(B) Quantifying the relative abundance of tens of thousands of transposon mutants of a given microbial species by INSeq. (1) The INSeq transposon (depicted
as an open rectangle) contains recognition sites for the type IIs restriction enzyme MmeI in its inverted repeats (black triangles); MmeI digests adjacent chro-
mosomal DNA 16 bp outside of the transposon. (2) Following digestion, sequencing adapters (gray ovals) are appended by ligation. These adapters can
contain sample-specific barcodes to allow sample pooling. (3) A limited number of cycles of PCR amplification of these uniformly sized molecules are per-
formed. (4) The resulting amplicons are sequenced using a massively parallel sequencing instrument. The sequence of each read indicates the genomic loca-
tion of the source transposon, and the relative abundance of each sequence mirrors the relative abundance of the corresponding transposon mutant in the
population. Comparison of these relative abundances in input versus output microbial populations identifies genes whose functions are required for fitness
in vivo.
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mice in the presence or absence of other
microbes. The representation of each ofthese mutants in the input community
is determined by targeted, massively
parallel sequencing of transposon-adja-Cell Metabolism 1cent chromosomal DNA (Figure 1B) and
compared to their representation in the
output community recovered from the2, August 4, 2010 ª2010 Elsevier Inc. 113
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mutant representation in the input versus
output communities can be used to infer
which microbial genes confer a fitness
advantage as a function of whatever
selective pressure is intentionally applied
to the system (e.g., manipulations of
host genotype, host diet, or which other
wild-type microbial species are intro-
duced together with the collection of
mutagenized strains of the indicator spe-
cies, etc.). In one example, INSeq high-
lighted the importance of a largely
unappreciated family of small molecules
(vitamin B12-like compounds called corri-
noids) as a microbial currency produced
by some species and required by others
in the mammalian gut, and identified the
broadly conserved but previously unan-
notated genes that likely mediate the
interspecies exchange of these corrinoids
(Goodman et al., 2009). Related trans-
poson mutagenesis strategies have also
been successfully applied to microbial
pathogens (Gawronski et al., 2009; Lan-
gridge et al., 2009; van Opijnen et al.,
2009).
Taken together, genomic, transcrip-
tomic, and INSeq datasets emanating
from these synthetic human gut commu-
nities provide the substrate for training
and evaluating algorithms for mapping
metabolic networks. One such method is
based on predictions of molecules that
function as ‘‘seeds’’ (acquired exoge-
nously from the environment), ‘‘intermedi-
ates,’’ or ‘‘products’’ (end products of
cellular metabolism) in an organism’s
metabolic reactions (Borenstein et al.,
2008). The extent of syntrophy (cross-
feeding) for any two organisms can
thus be viewed as the proportion of
seeds for one that are intermediates or
products in another, while competition
reflects the number of seeds that are
shared. Similar community metabolic
reconstructions that also integrate host
diet plus host seed/intermediate/product
metabolites should provide a powerful
tool for dissecting microbiota and host
cometabolism.
Challenges
What Is the Range of Normal
Variation in Microbiome Structure
and Function?
Independent studies suggest that our gut
microbiota may be a deeply personal part
of our biology (Costello et al., 2009; Turn-114 Cell Metabolism 12, August 4, 2010 ª201baugh et al., 2010; Qin et al., 2010). As
emphasized above, the environmental,
genetic, and/or dietary factors that drive
this variation are ill defined, and thus iden-
tifying pathologic configurations of the
microbiota (dysbiosis) is difficult. Core
(shared) gene families present in the
gut microbiomes of sampled populations
have been identified from searches of
databases of hierarchically organized
annotations of gene function (e.g., COG/
STRING, KEGG). However, caveats
apply. The largest study to date (Qin
et al., 2010) found that only one-third of
orthologous gene clusters conserved
across all 124 individuals in their survey
could be associated with even a broad
functional assignment. Notably, func-
tional classification schemes are based
on varying degrees of experimental vali-
dation, little of which has been carried
out in bacterial phyla that are prominently
represented in the gut.
The importance of considering the
dynamic nature of the gut ecosystem in
defining a normal configuration of the
microbiota is illustrated by the follow-
ing observations: controlled diet manipu-
lation in gnotobiotic mice colonized
with a complete human gut (fecal) micro-
biota revealed that the composition of
their human gut microbial communities
changed dramatically within a single day
after the animals were switched from a
plant polysaccharide-rich chow to a
high-fat, high-sugar ‘‘western’’ diet (Turn-
baugh et al., 2009b). The microbiota of
RELMb knockout mice also changes its
configuration in response to a high-fat
diet, although the animals themselves
are resistant to diet-induced obesity
(Hildebrandt et al., 2009). Thus, it will be
very important to develop ways to
‘‘correct for’’ or normalize the effects of
long- and short-term dietary choices
when connecting microbiota composition
to host metabotype. One approach could
be to develop a standard meal that is
administered over a period of time prior
to sampling of the microbiota, much like
a standard meal of glucose is consumed
prior to oral glucose tolerance tests.
Deciphering the Contributions
of Microbial Metabolism, Host
Metabolism, and Microbial-Host
Cometabolism
Dietary preferences may also influence
gut microbial community composition
and function in ways that produce0 Elsevier Inc.persistent and transmissible changes.
A b-porphyranase encoded by a gene
originally cloned and characterized
from the seaweed-associated bacterium
Zobellia glactanivoranswas recently iden-
tified in the genome of the human gut
symbiont Bacteroides plebeius. The pres-
ence of this glycoside hydrolase confers
the ability to process otherwise indigest-
ible marine plant polysaccharides present
in nori and other edible seaweeds. To
date, B. plebius has only been isolated
from individuals living in Japan, and
inspection of gut microbiome data sets
from North American and Japanese indi-
viduals revealed the presence of this
b-prophyranase in the latter but not the
former. These remarkable observations
are consistent with dietary selection of a
microbiome-associated metabolic char-
acteristic within a human population—a
characteristic that apparently was
acquired by horizontal gene transfer
from marine microbes associated with
nonsterile food (e.g., nori) to an
entrenched member of Japanese gut
microbial communities (Hehemann et al.,
2010). This finding provides a microbiome
counterpart to diet selection of H. sapiens
genotypes, such as amylase gene copy
number (Perry et al., 2007), that affect
our metabolic capabilities.
As studies increase our understanding
of normal variation of the human gut mi-
crobiota and of the metabolic potential
of differing microbial community configu-
rations, we will be challenged to decode
how host metabolism reacts to this enor-
mous microbial population (e.g., Claus
et al., 2008). Nontargeted MS surveys
will likely represent the beginnings of this
line of research, but obstacles in metabo-
lite annotation (assigning MS peaks) will
be even more significant than the difficul-
ties in gene annotation. In addition to
quantifying the direct impact of microbial
metabolites, another important aspect of
this challenge will be to identify host
receptors that translate microbial activity
in the lumen to the epithelium and
beyond. For example, a diverse family of
proteins, the G protein-coupled recep-
tors, populate members of the enteroen-
docrine cell lineage present in the
gut epithelium and have been shown
to respond to short-chain fatty acids
(SCFAs) and other microbial metabolites,
suggesting that microbial SCFAs could
play an important signaling role in addition
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harvest (Samuel et al., 2008). Similarly,
microbial deconjugation and modification
of bile acids influences both their deter-
gent activity and their signaling ability
(as activators of farnesoid X receptor
and other nuclear receptors that influence
host metabolism) (Hylemon et al., 2009).
Nontargeted MS studies have clearly
demonstrated that these are but a small
fraction of the metabolically important
molecules under microbial control (Martin
et al., 2007, Wikoff et al., 2009). As
emphasized above, strategies that inte-
grate (1) gnotobiotic mouse models,
colonized with carefully chosen synthetic
human gut microbiotas of increasing
complexity, or complete communities
harvested from humans with well-charac-
terized metabotypes, with (2) metage-
nomic and metabolomic pipelines, should
allow the connections between commu-




An understanding of the relationships
between diet, gut microbes, and host
biology promises to create another
dimension of personalized medicine,
where the flow of human and microbial
genes between members of a family
imprint metabotypes during postnatal
and subsequent periods of the human
lifecycle, and where intrapersonal (tem-
poral) and interpersonal variations in host
metabolism are found to have a microbial
underpinning.
This axis of personalized medicine,
guided by knowledge gleaned frommeta-
genomic studies of a person’s gut com-
munity, may evolve to include a number
of strategies. Microbial species, genes,
and gene products could provide a new
class of biomarkers for defining various
host physiologic and pathophysiologic
states and for evaluating therapeutic
interventions. New ways will likely be
found for highly selective manipulation
of the representation and/or metabolic
activities of organisms, or groups of
organisms whose niches (professions)
optimize the operations of the gut micro-
biota in various host contexts. This latter
approach could involve use of new
generations of ‘‘narrow spectrum,’’ taxa-
specific antimicrobials whose targets
are identified with tools such as INSeq,administration of seed compounds for
metabolic networks (‘‘designer prebi-
otics’’), or consumption of metabolically
engineered probiotic strains or groups of
microbes harvested from donors with
desired traits. Products normally gener-
ated by a healthy microbiota or their
synthetic derivatives could serve as new
generation therapeutic agents delivered
through a variety of routes, including
gut microbes themselves. Identifying
host signaling and metabolic pathways
that are targeted by the microbiota opens
the door to new therapeutic targets.
In principle, each of these approaches
could be applied to children at risk for
microbiome-associated metabolic disor-
ders, since this is a period when the
microbiota may be particularly amenable
to manipulation and reconfiguration.
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